The Global Health Body Raises Alert Over Acute Scarcity of Weight-Loss Medications

Less than a tenth of individuals that would benefit from obesity jabs including Wegovy can access them, states the global health agency as it releases its inaugural advice on the medications.

Given more than one billion people worldwide now living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication.

Based on estimates, more than two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidelines recognises that obesity is a chronic disease that can be addressed with holistic and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are key obstacles to widespread availability to the injections that can help people shift substantial weight, says the agency.

GLP-1 Therapy Shortage

Even in the current most optimistic outlook, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – less than 10% of the global need, per the health organization.

The advice calls on nations and manufacturers to widen access, via approaches such as licensing agreements.

Exclusive production rights on a key compound – the core ingredient of the drug Wegovy – is set to lapse in several countries in 2026.

The Way Obesity Jabs Operate

GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals reduce food intake.

Individuals typically begin shedding pounds within a few weeks of beginning the regular doses.

Evidence points to people may see weight return after a year of stopping the drug, because their typical food cravings resume.

Being carrying excess weight raises your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.

Obesity impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, per the health agency.